BEIJING--(BUSINESS WIRE)--#Shanghai--Phase II of the ATLATL Beijing International Innovation Center (referred to as "Beijing ATLATL"), located in the Zhongguancun Life Science Park, has officially commenced operations, marking the comprehensive launch of Beijing ATLATL.

Beijing ATLATL, initiated in 2021, has served more than 20 innovation teams, with total funding raised of more than 2 billion RMB.

Dr. PC Zhu, founder and CEO of ATLATL Innovation Center, stated that after more than two years in Beijing, ATLATL, leveraging its core R&D strength, has been vigorously constructing the Beijing ATLATL International Innovation Platform, pooling innovation and sourcing innovation. "Beijing has entered the top three in the world's top 100 science and technology clusters, boasting a strong technological foundation and numerous high-level scientists, with highly active innovation subjects. We are very grateful for the support of the government, the assistance of our partners, and the trust of innovation teams and clients. Today, Beijing ATLATL is officially fully operational. In the future, we will continue to build a diverse innovation ecosystem, continuously improving the innovation chain from basic research, applying research to industrial scenarios, gathering talents worldwide, generating attractive returns for investment, accelerating industrial transformation, fostering collaborative development, and helping enterprises reach the next milestone more quickly."

After the speeches, the first six biotech clients signed contracts to settle in Phase II of the Beijing ATLATL.

ATLATL adheres to a global perspective to advance scientific innovation development and enhance the innovation ecosystem. As a crucial part of this strategy, ATLATL continuously establishes connections with world-leading innovative R&D forces and conducts in-depth cooperation with multinational pharmaceutical companies, such as Novo Nordisk and Boehringer Ingelheim, empowering local innovation and global life science development. Both companies attended the event and delivered speeches to express their excitement regarding the expansion of cooperation geographically with their close partner, ATLATL.

ATLATL and Miltenyi jointly established the MITC Innovation Technology Center, creating an open innovation cooperation ecosystem in the field of Cell and Gene Therapy (CGT), and the two parties jointly built a diversified R&D pipeline with innovative project enterprises.

With its core strength, ATLATL has not only attracted multinational corporations but also numerous renowned research institutions to co-build cooperation platforms. At the launch ceremony, Beijing ATLATL signed agreements with global leading service and instrument enterprises, such as Charles River Labs and Danaher, jointly empowering new drug development and creating more value in the future.

The total building area of Beijing ATLATL is around 100,000 square feet, equipped with Class A research and development spaces, including over 30 turn key laboratories and two multifunctional GMP plants, as well as a PCR clinical testing center. It provides resident enterprises with the state-of-the-art R&D spaces and professional facilities.

ATLATL will build ATLATL Innovation Cluster(Beijing) with an approximate building area of 1 million square feet in the Life Science Park, including 500,000 square feet R&D / commercialization center, facilitating the acceleration of Beijing's "Life Valley".

In this innovative park, ATLATL has built an open, international, and creative ecosystem. Potential innovative seeds optimized their innovation paths through ATLATL, reducing innovation costs, shortening trial and error cycles, and with ATLATL's assistance, connecting with global top resources to grow rapidly. At the same time, well-known enterprises and institutions cooperating with ATLATL can also explore innovative technologies in a timely manner and rapidly promote the transformation of innovative achievements through various empowerment methods.

Through sourcing and pooling innovation, ATLATL quickly connects China's biopharmaceutical innovation "seeds" with international resources, accelerates the development of "Life Valley" in Beijing, creates a globally leading innovation platform, and builds a world-class biopharmaceutical innovation cluster.

About ATLATL Beijing

ATLATL Beijing is an innovation platform in the field of life health technology that integrates research and development centers, acceleration and transformation, and early-stage incubation. Benchmarking international top-level biopharmaceutical R&D laboratory standards, it is designed and built with Class A-level research and development laboratory spaces, equipped with high-quality office and business spaces, and extensively gathers multinational corporations, well-known domestic pharmaceutical companies, high-level research institutes, and medical institutions. ATLATL Beijing integrates cutting-edge R&D resources to provide resident enterprises with high-end research and development equipment, refined laboratory operation and EHS management, professional on-site CRO technical support and research and development assembly management system, as well as complete supporting resources to achieve the rapid transformation of cutting-edge technology.

Contacts

Jo Lee, [email protected]